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Abstract Vincristine (VCR) is a mainstay of treatment of
hematologic malignancies and solid tumors due to its well-
defined mechanism of action, demonstrated anticancer
activity and its ability to be combined with other agents. VCR
is an M-phase cell cycle-specific anticancer drug with activity
that is concentration and exposure duration dependent. The
pharmacokinetic profile of standard VCR is described by a bi-
exponential elimination pattern with a very fast initial distri-
bution half-life followed by a longer elimination half-life.
VCR also has a large volume of distribution, suggesting dif-
fuse distribution and tissue binding. These properties may
limit optimal drug exposure and delivery to target tissues as
well as clinical utility as a single agent or as an effective
component of multi-agent regimens. Vincristine sulfate lipo-
some injection (VSLI), Marqibo, is a sphingomyelin and
cholesterol-based nanoparticle formulation of VCR that was
designed to overcome the dosing and pharmacokinetic limi-
tations of standard VCR. VSLI was developed to increase the
circulation time, optimize delivery to target tissues and
facilitate dose intensification without increasing toxicity. In
xenograft studies in mice, VSLI had a higher maximum tol-
erated dose, superior antitumor activity and delivered higher
amounts of active drug to target tissues compared to standard
VCR. VSLI recently received accelerated FDA approval for
use in adults with advanced, relapsed and refractory Phila-
delphia chromosome-negative ALL and is in development for
untreated adult ALL, pediatric ALL and untreated aggressive
NHL. Here, we summarize the nonclinical data for VSLI that
support its continued clinical development and recent
approval for use in adult ALL.
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Introduction
Introduced over 45 years ago, vincristine (VCR) remains a
potent and widely used anticancer agent, particularly for
childhood and adult hematologic malignancies and solid
tumors including sarcomas. However, sub-optimal phar-
macokinetic properties and dose-related neurotoxicity
prevent realization of the full potential of this agent. VSLI
(vincristine sulfate liposome injection, 0.16 mg/mL (Mar-
qibo)) is a novel formulation of VCR that encapsulates
the drug in sphingomyelin and cholesterol nanoparticles.
The VSLI liposome is distinct from alternate liposomes
used in other approved pharmaceutical products and is
uniquely suited to contain, deliver, and dose intensify
VCR. Here, we review the nonclinical investigations which
demonstrate VSLI’s optimized pharmacokinetic profile,
enhanced drug delivery to target cancer tissues and
increased activity in tumor models. These and other non-
clinical studies supported the clinical development of VSLI
which led to the recent approval of VSLI by the US FDA
for treatment of adult patients with Philadelphia chromo-
some-negative (Ph-) acute lymphoblastic leukemia (ALL)
in second or greater relapse or whose disease has pro-
gressed following two or more antileukemia therapies.
Vincristine background
VCR was initially discovered in a screening program
investigating the potential antidiabetic properties of
extracts from the widely cultivated white- or pink-flowered
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periwinkle plant, Cantharanthus roseus (formerly known as
Vinca rosea Linn) [1–3]. Although ineffective as an oral
antidiabetic treatment, the periwinkle extract was found to
potently inhibit leukocyte production and maturation.
Significant antileukemia activity of the alkaline fractions in
animal models led to the subsequent isolation of several
alkaloids, most potently from the leaves, which include
the compounds now known as vincristine, vinblastine,
vinleurosine and vinrosidine.
VCR is a highly active cell cycle-dependent anticancer
drug. Extensive research on the mechanism of action of
VCR has demonstrated that it binds to tubulin causing
microtubule depolymerization, metaphase arrest and
apoptotic death of cells undergoing mitosis [4, 5]. Tubulin
is essential for the normal polymerization of mitotic spin-
dle microtubules. VCR binding to spindle microtubules
alters spindle structure and function in a concentration-
dependent manner. At low concentrations, VCR stabilizes
the spindle apparatus which prevents chromosome segre-
gation and results in metaphase arrest and inhibition of
mitosis. At higher concentrations, disruption and total
depolymerization of microtubules has been observed. The
effect of short-term VCR exposure on mitotic arrest is
reversible and cells can proceed normally through the cell
cycle if the drug is removed. In contrast, long-term expo-
sure to high concentrations of VCR results in lethal cyto-
toxicity [6–10]. Thus, the antitumor potency of VCR is
dependent on the concentration and duration of exposure
and the number of cells transiting through mitosis during
the period of drug exposure. Interference of microtubule
function also disrupts other cellular processes that involve
microtubules, such as intracellular transport and cellular
organization [4, 11, 12]. As a result of its interruption of
microtubule function, especially evident during M-phase,
cells accumulate in metaphase contributing to VCR-
induced cytotoxicity [11, 13].
VCR-mediated antitumor activity may also include an-
tivascular and antiangiogenic properties. In vitro, VCR
inhibits the secretion of angiogenic factors such as vascu-
lature endothelial growth factor (VEGF) by normal and
drug-resistant human tumor cells [14], inhibits the prolif-
erative activity and formation of capillary networks in
cultured endothelial cell assays, and reduces the migratory
activity of tumor cells in Matrigel assays [15]. In mouse
models, VCR and other vinca alkaloids decrease vascular
flow in tumors and normal tissues [16–19]. Antiangiogenic
activity and decreased microvasculature density in tumor
xenograft models have been described following VCR
therapy [20]. The role of microtubules in these effects has
not been established.
After clinical trials demonstrated anticancer activity in
humans, the US FDA granted marketing approval for
VCR in 1963. It has subsequently become an essential
component of multi-drug chemotherapeutic regimens for
the treatment of hematologic malignancies [21]. Early
demonstration of VCR’s activity and dose–response
relationship in acute leukemia and Hodgkin’s lymphoma
led to clinical investigations in additional cancers [1].
Standard VCR has subsequently been approved for use
in many neoplasms, including ALL, and in combination
with other agents for the treatment of Hodgkin’s disease,
non-Hodgkin’s lymphoma (NHL), rhabdomyosarcoma,
neuroblastoma and Wilms’ tumor. The usual dose of
VCR for adults is 1.4 mg/m2 administered intravenously
once a week. However, the oncology community and
most vincristine-containing cancer treatment regimens
routinely limit individual standard vincristine doses to
2.0 mg (i.e., dose capping) in an attempt to minimize
neurotoxicity.
Despite its potent antineoplastic activity, however, VCR
has several pharmacological limitations. VCR plasma
pharmacokinetics are described by a bi-exponential profile
with a very short and extensive distribution half-life fol-
lowed by a longer elimination half-life (Fig. 1); the volume
of distribution is large, suggesting wide and diffuse dis-
tribution and perhaps extensive tissue binding (Table 1).
These pharmacological properties may limit its optimal
clinical benefit by limiting plasma and cancer tissue Cmax
and cancer tissue drug exposure.
Liposome overview
Liposomes are small phospholipid vesicles that are versa-
tile drug carriers which can be used to overcome the
potential barriers of many drugs and allow effective
delivery to their target tissues such as tumors (reviewed in
[22–27]). Liposomes are simple, self-assembling vesicles
with either single phospholipid bilayers (unilamellar) or
multiple phospholipid bilayers that enclose an aqueous
core, which can include a therapeutic drug ‘‘payload’’.
Liposomes can be used to solve sub-optimal pharmaceu-
tical properties such as low solubility, instability and rapid
metabolism; they can also alter the distribution of drugs
and offer the potential of selective delivery to the site of
action [22, 28]. To be effective as a delivery system, lip-
osomes balance stability and time in the systemic circula-
tion with release, or bioavailability, of the drug at the target
site. VCR exhibits low solubility in aqueous solutions at
physiological pH in vitro and has a rapid initial plasma Cl
and extensive volume of distribution in vivo (Fig. 1;
Table 1) [4, 5, 12, 29]. These physico-chemical and phar-
macokinetic properties combined with VCR’s narrow
therapeutic index and strong anticancer activity make it
well suited for liposome technology to improve its utility in
cancer therapy.
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For many liposome technology–enhanced drugs, par-
ticularly those that are slowly released from their liposome,
the pharmacokinetic properties become similar to that of
the liposome itself [25]. The initial formulation of liposo-
mal VCR used distearoylphosphatidylcholine and choles-
terol liposomes and a pH gradient to load the drug into the
vesicles. This formulation demonstrated a longer circula-
tion time, enhanced tumor delivery and antitumor activity
and decreased toxicity compared to the standard formula-
tion of VCR [29–31]. Subsequent development of liposo-
mal formulations for VCR to optimize its pharmacokinetic
properties, such as increased circulation time and enhanced
delivery of the drug to target tissues, led to the identifica-
tion and development of sphingomyelin/cholesterol (SM/
Chol) liposomes [32–34]. These SM/Chol liposomes offer
the advantage of improved drug loading, retention and
release, longer plasma circulation time and enhanced tar-
get-tissue accumulation without the technical challenges,
and manufacturing expense, of surface-modified liposome
technologies, for example, liposomes using Polyethylene
Glycol (PEG) polymers.
VSLI overview
VSLI, Marqibo, is a proprietary sphingomyelin- and
cholesterol-based nanoparticle formulation of VCR that
was designed to overcome the dosing and pharmacokinetic
limitations of standard VCR. As described above, pro-
longed exposure of cells to VCR enhances its in vitro
cytotoxicity due to the fact that at longer exposure times a
greater proportion of the cells will have passed through
mitosis, where VCR exerts its cytotoxic effects [35–37].
The liposomal carrier component of VSLI, composed of
sphingomyelin and cholesterol, was specifically designed
to facilitate the loading and retention of VCR, to prolong
the circulation time of encapsulated VCR, to increase
extravasation into tumors and to slowly release the drug in
the tumor interstitium [38, 39]. These characteristics result
in high levels of encapsulated drug in target tissues and a
long duration of exposure of tumor cells to therapeutic drug
concentrations as VCR is slowly released from the lipo-
somes, leading to enhanced activity.
VSLI nonclinical pharmacokinetics
VSLI has a long circulation time and remains in the plasma
instead of being rapidly and widely distributed in tissues
like unencapsulated VCR [40–42]. The clearance of lipo-
somes is largely a function of uptake by the mononuclear
phagocytic system (MPS) which is influenced by the lipid
composition, size of the nanoparticle and the extent of
protein binding, or opsonization, by serum proteins [25].
The SM/Chol lipid composition and the *100 nm mean
particle size of the VSLI liposome contribute to low protein
binding that result in a longer circulation time for the
nanoparticle [38, 43, 44]. In vitro protein binding assays
demonstrated negligible levels (limit of detection 4.5 lg
protein/mg lipid) of bovine or human plasma proteins
adsorbed to VSLI which was consistent with the biophys-
ical properties of the SM/Chol liposome, that is, uncharged
and tight lipid packing [41, 44] (unpublished data, Talon
Therapeutics). Approximately 18–39 % of encapsulated
VCR was released at 24 h at 37 C in an in vitro assay
using human plasma. These characteristics of the liposome
facilitate VSLI accumulation in tumors and tissues of the
MPS due to the larger microvascular fenestrations in those
tissues [40]. Subsequently, the nanoparticles slowly release
the VCR in those tissues with an in vivo half-life of
approximately 24 h.
The pharmacokinetic profile of VSLI was established in
mice, rats and dogs. The pharmacokinetic properties of
VSLI are consistent across species with VSLI showing
substantially lower total VCR clearance and volume of




























Fig. 1 Plasma vincristine concentration following administration of
2 mg/m2 of VCR (dashed lines) or VSLI (solid lines) to rats.
Vincristine drug concentrations were measured in plasma from
Sprague–Dawley rats (N = 3/sex, except at 120 h, N = 5) at the
indicated timepoints post-dose of 2 mg/m2 VSLI (solid lines) or
vincristine (dashed lines). Symbols indicate the following: Male VCR
(open circle), Female VCR (open square), Male VSLI (filled circle),
Female VSLI (filled square)














VSLI 5,662 63,438 6.9 NAa 32 383
VCR 148 806 0.2 36.5 2,488 113,513
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the curve (AUC) than VCR (Table 2). These data show in
all three species that, compared to VCR, VSLI is not rap-
idly distributed to tissues in the first few minutes after
administration and that it remains in the systemic circula-
tion and subsequently distributes into MPS tissues and
tissues with fenestrated vasculature (e.g., bone marrow,
lymph nodes, spleen and tumors). Linear relationships
between VSLI dose and total VCR AUC and Cmax (max-
imum concentration) were observed after single doses in
rats over the dose range of 1.0–3.0 mg/m2 and in dogs over
the range of 0.5–1.1 mg/m2 (not shown). Figure 1 and
Table 1 illustrate the pharmacokinetic profile and calcu-
lated parameters of VSLI in rats following an IV dose.
Following a brief initial decline, the reduction in total VCR
concentration was minimal, suggesting a delay phase. The
extensive early rapid distribution phase seen with VCR
does not occur with VSLI. Total (encapsulated ? free)
VCR concentration declined monoexponentially. Notably,
Vss for total VCR after VSLI injection was close to plasma
volume, indicating VSLI is confined within the plasma
compartment for a longer period of time compared to VCR,
and subsequently circulates repeatedly through target tis-
sues and then accumulates in tissues with fenestrated vas-
culature, in particular, tumors and tissues of the MPS as
described above. The disposition kinetics of the lipid
component of VSLI was highly correlated with those for
total VCR, indicating that the VCR is retained in the
liposome and that the pharmacokinetics of VCR after VSLI
administration is governed by the pharmacokinetics of the
liposomes [40].
The pharmacokinetic profile in most dogs also showed
an initial delay phase followed by a slow decline in total
VCR levels with a prolonged half-life (Fig. 2). However,
some dogs (17 %) showed an early rapid reduction fol-
lowed by a slow decline in total plasma VCR that sug-
gested a bi-exponential profile. Repeated doses of VSLI at
2 week intervals revealed that dogs retained their individ-
ual characteristics, that is, they continued to exhibit their
mono or bi-exponential profile for the duration of the study.
Analysis of the VCR in plasma demonstrated that [90 %
of total VCR remained encapsulated so that the drug was
not rapidly released in the systemic circulation. Thus, the
difference in plasma pharmacokinetic profile was not due
to release of the drug from the liposome and may represent
differences in the capacity of individual animal MPS.
The extent of VCR metabolism and the metabolic pro-
files of VCR in rat urine and bile were similar for VSLI and
VCR, indicating bioavailable VCR was metabolized simi-
larly for both formulations. Radio-labeled mass-balance
studies in rats showed that approximately 90 % of the
administered dose of VSLI was recovered in the urine and
feces over 72 h post-dose, a delay of 12–48 h compared to
the standard VCR formulation. This is consistent with
prolonged circulation of VSLI as well as the prolonged
retention of VCR within the liposomes in vivo. From either
Table 2 Cross-species comparison of pharmacokinetic parameters
Dose (mg/m2) Cmax (ng/mL) AUCinf (ngh/mL) t1/2k1 (h) t1/2kz (h) Cl (mL/h/m2) Vss (mL/m2)
Mousea
VCR 6 1,470 11,100 0.19 24.8 494 17,214
VSLI 6 22,600 351,100 10.8 16 242
Rat
VCR 2 148 806 0.2 36.5 2,488 113,513
VSLI 6,271 89,910 6.0 23 244
Dog
VCR 0.8 31 62 0.2 8.5 15,032 132,453
VSLI 0.8 656 543 0.2 10.6 1,474 5,436



























Fig. 2 Plasma vincristine concentration following administration of
0.8 mg/m2 VCR or VSLI to dogs. Vincristine drug concentrations
were measured in plasma from dogs at the indicated timepoints post-
dose of VSLI or vincristine. Symbols indicate the following: VSLI
Monoexponential (N = 12, closed diamond), VSLI Bi-exponential
(N = 2, filled square), VCR (N = 14, filled triangle)
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formulation, less than 10–20 % of the total radioactivity in
the bile and urine was present as metabolites (Talon
Therapeutics, data on file and Castle et al. 1976, Castle and
Mead 1978) [45, 46]. The major route of excretion of
radioactivity in VSLI-treated rats was biliary since the
majority of radioactivity (75 %) was recovered in the feces.
The maximum fecal excretion occurred between 24 and
72 h, whereas the maximum urinary excretion occurred
between 0 and 12 h. Combined, these data demonstrate
retention of the encapsulated drug in the liposomes and
slow release of the VCR in the target tissues.
The comparative tissue distribution of total VCR fol-
lowing a single IV bolus injection of either VSLI or VCR
was assessed in rats and mice. Following administration of
VSLI, the maximum plasma concentration (Cmax) of VCR
in most tissues was between 4 and 24 h with the majority
of tissues peaking around 16 h. For most tissues from
VSLI-treated animals, tissue to plasma concentration ratios
increased over time and peaked at 72 h after VSLI injec-
tion, indicating progressive accumulation of radio-labeled
drug from plasma into the tissues [42, 47]. The tissue
distribution of total VCR was slower following adminis-
tration of VSLI than after VCR, and more extensive
accumulation was observed in tissues of the MPS such as
the spleen, liver, lymph nodes and bone marrow (Fig. 3).
The rank order of tissues based on Cmax demonstrated that
total VCR concentrations in MPS tissues and in ovaries
were substantially higher than in other organs or tissues.
The lowest radioactivity levels were observed in brain,
spinal cord, nerves and muscle. Higher exposures, as
measured by AUCinf, of VCR were observed in spleen (12
fold), lymph nodes (tenfold), liver (fourfold) and bone
marrow (twofold) following a radio-labeled dose of VSLI
compared to VCR (Table 3). Thus, preferential accumu-
lation of the liposomes and subsequent slow release of
VCR in target tissues important in hematologic malignan-
cies following administration of VSLI results in higher and
prolonged tissue drug levels providing superior drug
delivery to those tissues than the same dose of standard
formulation of VCR.
The extravasation kinetics and preferential accumulation
of VSLI in tumors was further investigated using intra-vital
microscopy imaging in mice implanted with LX-1 cells, a
xenograft model of human small-cell carcinoma [48].
Significantly faster extravasation occurred in tumor vessels
than in nontumor tissues after a single dose of fluorescently
labeled VSLI liposomes. The interstitial amounts of drug
were approximately 70-fold higher in tumor tissues com-
pared to nontumor tissues at 1 h and remained higher at
48 h. Combined, these distribution data are consistent with
VSLI exiting the systemic circulation, accumulating at the
site of tumors where they act as a reservoir for the release
of localized VCR to enhance the antitumor activity.
VSLI nonclinical pharmacodynamics
The prolonged plasma circulation time and increased VCR
penetration and concentration in tissues (i.e., passive tar-
geting) of VSLI translated into enhanced antileukemia
activity compared to standard VCR without additional
toxicity (i.e., widens the therapeutic index). Examples of
this are shown in Fig. 4. Mice bearing Namwala xenograft
tumors treated with VSLI showed better tumor growth
suppression at 1.0, 1.5 and 2.5 mg/kg compared to animals
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Fig. 3 Tissue total vincristine concentration following administration
of VSLI (a) or VCR (b) to rats. Rats were administered a single bolus
dose of 2.0 mg/m2 of either [3H]Vincristine or VSLI that had
[3H]Vincristine encapsulated into the liposome. Tissue drug levels
were measured up to 72 h post-dose by liquid scintillation counting of
tissue samples. The bars represent samples taken at the following
times: 4 h (open bars), 12 h (black bars), 24 h (gray bars)
Table 3 Comparison of tissue exposure to vincristine following
administration of either VSLI or VCR





VSLI 381,154 28,202 66,333 40,936
VCR 30,765 6,496 6,420 17,767
Ratio VSLI/VCR 12.4 4.3 10.3 2.3
Cancer Chemother Pharmacol (2013) 71:555–564 559
123
growth suppression was dose dependent for both agents;
the maximum tolerated dose for VSLI was 2.5 mg/kg
versus 1.5 mg/kg for VCR. The antitumor activity of VSLI
was greater at each dose level with maximal activity at the
MTD of 2.5 mg/kg, a dose unachievable with standard
formulation VCR. Similarly, in the LX-1 human small-cell
lung carcinoma model, VSLI demonstrated greater antitu-
mor activity than an equivalent dose of VCR at 1.0 mg/kg
administered q7d 9 3 (Fig. 4b) [48].
The superior antitumor activity of VSLI compared to that
of VCR was further demonstrated in a variety of human
tumor xenograft and murine syngeneic models representing
several cancer types. Table 4 provides a summary of studies
conducted using either a single administration or a multi-
dose regimen. Overall, in 18 animal tumor models repre-
senting 11 different cancer indications, VSLI was more
active than VCR in 11 tumor models representing 8 cancer
indications (Table 4). Improved activity of VSLI over VCR
was observed using a variety of dosing schedules and routes
of tumor implantation. In all cases, VSLI antitumor activity
was equivalent to or exceeded that of the same dose level of
VCR; in no case was VSLI activity less than that seen at an
equivalent dose level of VCR. The antitumor activity of
VSLI was dose dependent in 13/18 of the tumor models
evaluated (Table 4). Three models were not sensitive to
either VSLI or VCR (B16/BL6 melanoma, NCI-H460
NSCLC, and HT29 colon carcinoma) while one (SR lym-
phoma) was very sensitive to both VSLI and VCR. Further,
as measured by changes in body weight or mortality,
VSLI was tolerated at higher dose levels than VCR. Com-
bined, these nonclinical data demonstrate that VSLI has
potent antitumor activity which exceeds that of conven-
tional VCR.
Data from Leonetti et al. [49] demonstrated that VSLI is
also effective in three drug-resistant tumor models that
over-express P-glycoprotein. When treated with standard
VCR, M14 melanoma, MCF-7 breast carcinoma and LoVo
colon carcinoma cells showed growth delay, whereas drug-
resistant variants of each of those cell lines were resistant
to growth inhibition by standard VCR. Xenograft tumors
grown in mice from each of those cell lines were sensitive
to standard VCR, whereas their resistant variants showed
no delay in tumor growth. In contrast, tumors from both the
parental cell lines and the drug-resistant variants were
sensitive to VSLI and resulted in significant tumor growth
delay. Immunohistochemical analysis of VSLI-treated
tumors further demonstrated massive necrosis and apop-
tosis. These data suggest that VSLI may be effective in
drug-resistant tumors that express increased levels of
P-glycoprotein.
VSLI clinical experience
The pharmacokinetics of VSLI in humans is similar to
that observed in nonclinical species. Specifically, VSLI is
a long circulating, slow-release nanoparticle formulation
of VCR that remains within the plasma compartment for a
prolonged period of time compared to standard VCR
(Fig. 5; Table 4). Due to the slow release of VCR from
the liposome, the plasma concentration profile of total
VCR represents that of the encapsulated drug. Unlike the
very rapid distribution phase observed with standard VCR,
a delay of 3–12 h in VCR clearance from plasma is
observed following VSLI administration, resulting in total
VCR levels that remain relatively constant before declin-
ing with time. This delay phase contributes significantly
to the plasma AUC following VSLI administration. Sub-
sequent to this delay phase, a wide variance in profiles
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Fig. 4 VSLI and VCR antitumor activity in Namawala (a) and LX-1
(b) tumor bearing mice. Namawala (human lymphoma model) or LX-
1 (human SCLC model) tumor cells were implanted subcutaneously
into SCID mice. Mice received vehicle (dotted line), VCR (dashed
lines), or VSLI (solid lines) on days 11, 18 and 25 post-implantation.
Data represent mean ± SD, N = 5–10. The symbols indicate the
following treatments: Vehicle-treated control (-), vincristine 0.5 mg/
kg (?), 1.0 mg/kg (open circle), 1.5 mg/kg (open square); VSLI
1.0 mg/kg (filled circle), 1.5 mg/kg (filled square), 2.5 mg/kg (filled
diamond)
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declines in plasma concentrations of total VCR to a range
of apparent bi-exponential profiles. This variability in
pharmacokinetic profile represents the clearance of the
liposomes from the plasma and the capacity of the MPS
system to mediate that clearance. Importantly, no differ-
ences in tolerability were seen between subjects with
monoexponential and bi-exponential profiles. And gender,
age, BSA, or cancer type did not affect Cl or exposure
(AUCinf) (Table 5).
VSLI has been studied in 20 clinical trials and 2 com-
passionate use programs. Malignancies represented in these
trials include acute lymphoblastic leukemia (ALL), non-
Hodgkin’s lymphoma (NHL), Hodgkin’s lymphoma, and
solid tumors such as metastatic melanoma and lung cancer.
Both adults and children have been studied. As a result of
these studies and the strong historical data demonstrating
clinical activity of the standard VCR in hematologic can-
cers, VSLI is being developed in ALL and other hemato-
logic malignancies.
ALL is a malignant disease of B- or T-lymphocytes
characterized primarily by failure of proper cellular mat-
uration and consequent aberrant cell proliferation. Malig-
nant proliferation of lymphoblasts in the bone marrow and
blood suppresses normal hematopoesis and may lead to
infiltration of extramedullary sites such as the liver,
spleen, thymus, meninges and gondads [50]. The disease
is characterized by rapid progression and death if not
successfully treated. Sequential modifications of treatment
protocols have led to remarkable improvement in survival
outcome in pediatric and adolescent ALL patients with
survival rates exceeding 80 %. Despite the remarkable
success in treatment of childhood and adolescent ALL,
Table 4 Summary of VSLI versus VCR antitumor activity in 18 human tumor xenograft models
Tissue origin Tumor
modela




Leukemia P388c (IP) Single Moderate VSLI VSLI [ VCR*
Lymphoma Namalwa q7d 9 2, q7d 9 3 Moderate VSLI, VCR VSLI [ VCR*
Lymphoma RL q7d 9 3 High VSLI, VCR VSLI [ VCR
Lymphoma DoHH2 q7d 9 3 High VSLI, VCR VSLI = VCR
Lymphoma SR q7d 9 2 High None Unable to assess
SCLC LX-1 Single Weak VSLI VSLI [ VCR
SCLC LX-1 q7d 9 3 Moderate NA VSLI [ VCR*
SCLC NCI-H69 Single High VSLI, VCR VSLI = VCR
SCLC DMS273 Single Moderate VSLI, VCR VSLI = VCR
Breast carcinoma MX-1 Single Moderate VSLI, VCR VSLI [ VCR
Breast carcinoma MX-1 q21d 9 2, q21d 9 3 High VSLI, VCR VSLI [ VCR*
Breast carcinoma MX-1 q7d 9 3 High VSLI, VCR VSLI [ VCR
Breast carcinoma MX-1 q7d 9 3 High VSLI, VCR VSLI [ VCR
Renal carcinoma RXF393 Single Weak VSLI VSLI [ VCR*
Prostate carcinoma PC-3 Single Moderate VSLI VSLI [ VCR
Prostate carcinoma PC-3 q7d 9 3 High VSLI, VCR VSLI = VCR
Prostate carcinoma PC-3 (OT) q7d 9 3 Moderate None VSLI C VCR
Kaposi’s sarcoma My1 q7d 9 3 Weak VSLI, VCR VSLI C VCR
Melanoma B16/BL6c (IV) Single Not sensitive None Unable to assess
Melanoma B16/BL6c q7d 9 3 Not sensitive None Unable to assess
NSCLC NCI-H460 Single Not sensitive None Unable to assess
Colon carcinoma HT29 Single Not sensitive None Unable to assess
Multiple myeloma LAGj-1A q7d 9 3 Moderate VSLI VSLI [ VCR
Multiple myeloma LAGj-1B q7d 9 3 Not sensitive VSLI VSLI [ VCR
IV intravenous, IP intraperitoneal, NA not applicable (only one dose tested), OT orthotopic, SCLC small-cell lung cancer
a Tumors were human xenograft models implanted subcutaneously, unless specified
b Repeat-dose schedules were once a week for 2 or 3 cycles (q7d 9 2 or q7d 9 3) or every 3 weeks for 2 or 3 cycles (q21d 9 2 or q21d 9 3).
cMurine tumor model
* Statistically significant difference (p \ 0.05)
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adult ALL patients are underserved by existing treatment
options as reflected by the poor survival rates and extre-
mely poor outcomes in the relapsed setting. Recent trials
have shown that 65–85 % of adults will achieve a com-
plete remission; however, the duration of these responses
is often short, especially in older adults [51, 52]. When
relapsed, adult ALL has a poor long-term survival rate of
20–40 % [53, 54]. Currently there is no clear standard of
care or guidance for the treatment of advanced, relapsed
and/or refractory ALL.
Based on the clear unmet medical need, the superiority of
VSLI over standard VCR in nonclinical studies and
encouraging activity in Phase 1 trials, a multi-national piv-
otal, Phase 2, single-arm, open-label trial (NCT00495079) of
high dose (2.25 mg/m2), weekly VSLI monotherapy was
conducted in heavily pre-treated adults with advanced,
relapsed and refractory B or T cell lineage Philadelphia
chromosome-negative (Ph-) ALL. VSLI monotherapy
resulted in meaningful clinical outcomes; the CR/CRi rate
and overall response rates were 20 % and 35 %, respectively
[55]. VSLI monotherapy was effective as third-, fourth-, and
fifth-line therapy and in patients refractory to other single-
and multi-agent therapies. The median uncensored CR/CRi
duration was 23 weeks (range 5–66 weeks), and 5 patients
were long-term survivors. Importantly, 12 patients who were
ineligible for immediate hematopoietic cell transplant were
able to subsequently receive a transplant. The toxicity profile
of high-dose VSLI was predictable, manageable and com-
parable to that of standard dose and formulation VCR despite
the delivery of large, normally unachievable, individual and
cumulative doses of VCR. These studies led to the acceler-
ated approval of VSLI by the FDA for the treatment of adult
patients with Ph- ALL in second or greater relapse or whose
disease has progressed following two or more antileukemia
therapies.
Summary
VSLI is a proprietary sphingomyelin- and cholesterol-
based nanoparticle formulation of VCR that was designed
to be different from and overcome the dosing and phar-
macokinetic limitations of standard VCR. In nonclinical
studies, VSLI: 1) increases the plasma circulation time; 2)
increases tumor tissue delivery by preferential extravasa-
tion from fenestrated (‘‘leaky’’) vasculature; 3) accumu-
lates in tumor tissues; and 4) slowly releases VCR in tumor
tissues instead of the systemic circulation. These unique
pharmaceutical properties resulted in superior nonclinical
pharmacokinetic properties in mice, rats and dogs and
translated into increased efficacy in 11 murine tumor
models compared to standard VCR. Clinical trials dem-
onstrated safety, tolerability, and promising activity of
VSLI in adults with advanced relapsed/refractory leukemia
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Fig. 5 Mean plasma concentration–time profile of total VCR in
humans following IV administration of VSLI at 2.25 mg/m2. Plasma
was collected from adult Ph-chromosome-negative relapsed/refrac-
tory patients, N = 12. Total VCR concentrations were measured at
the indicated times post-dose of VSLI using a validated LC/MS–MS
method. The lower limit of quantitation (LLOQ) for vincristine
sulfate was 1.00 ng/mL. Pharmacokinetic parameters for total VCR
concentrations (encapsulated and free) in plasma were calculated
from the plasma concentration–time data using a noncompartmental
analysis (NCA) method (WinNonlin Professional Network Edition,
Version 5.2, Pharsight Corp, Palo Alto, CA, USA)
Table 5 Mean plasma PK parameters of total vincristine in humans following IV administration of VSLI at 2.25 mg/m2
Cmax (ng/mL) Tmax (h) AUC0–last (ng h/mL) AUC0-inf (ng h/mL) t1/2 (h) CL (mL/h) Vd (mL) Vdss (mL) MRT0–inf (h)
N 13 13 13 12 12 12 12 12 12
Mean 1,220 – 13,732 14,566 7.66 345 3,569 2,914 9.63
SD 229 – 5,666 6,368 3.18 177 1,924 1,219 4.44
CV % 18.8 – 41.3 43.7 41.5 51.2 53.9 41.8 46.1
Min 919 1.08 6,975 7,036 4.49 148 1,540 1,803 5.38
Median 1,230 1.25 13,502 13,680 6.61 302 3,254 2,601 8.43
Max 1,720 4.17 24,036 26,074 12.6 783 7,754 6,500 17.7
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